While our current B cell focused study highlights a mechanism by which BTKi may limit B-cell pro-inflammatory contributions in MS, mounting evidence also indicates that anti-inflammatory B cells and/or plasma cells can traffic into the inflamed CNS, where they may exert important anti-inflammatory, and potentially tissue protective, effects [44, 46]. Here, IBTK is linked to myeloid sarcoma.